157 related articles for article (PubMed ID: 24586482)
1. rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus.
Liu Y; Xu Z; Wang Y; Li X; Liu L; Chen L; Xin S; Xu D
PLoS One; 2014; 9(2):e89015. PubMed ID: 24586482
[TBL] [Abstract][Full Text] [Related]
2. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
3. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
Liu Y; Li X; Xin S; Xu Z; Chen R; Yang J; Liu L; Wong VW; Yang D; Chan HL; Xu D
J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
[TBL] [Abstract][Full Text] [Related]
4. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
[TBL] [Abstract][Full Text] [Related]
5. Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
Fan J; Wang Y; Xiong H; Guo X; Cheng YC
J Gen Virol; 2014 Nov; 95(Pt 11):2523-2530. PubMed ID: 25028473
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.
Zhong Y; Lv J; Li J; Xing X; Zhu H; Su H; Chen L; Zhou X
Antiviral Res; 2012 Jan; 93(1):185-90. PubMed ID: 22138714
[TBL] [Abstract][Full Text] [Related]
7. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues.
Wang F; Wang H; Shen H; Meng C; Weng X; Zhang W
Clin Ther; 2009 Feb; 31(2):360-6. PubMed ID: 19302908
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
[TBL] [Abstract][Full Text] [Related]
9. Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.
Wu S; Fukai K; Imazeki F; Arai M; Kanda T; Yonemitsu Y; Yokosuka O
Dig Dis Sci; 2011 Apr; 56(4):1207-14. PubMed ID: 20927588
[TBL] [Abstract][Full Text] [Related]
10. Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
Liu Y; Xin S; Ye X; Chen R; Xu Z; Li X; Ye H; Cheng S; Xu D
Antivir Ther; 2016; 21(1):9-16. PubMed ID: 26079809
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of therapy in patients with chronic hepatitis B virus.
Arrese E; Basaras M; Blanco S; Ruiz P; Cisterna R
Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):736-40. PubMed ID: 19550344
[TBL] [Abstract][Full Text] [Related]
12. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
[TBL] [Abstract][Full Text] [Related]
13. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
15. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
[TBL] [Abstract][Full Text] [Related]
16. Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient.
Zhang Q; Chen J; Pan M; Liu J; Liu T; Zhou YH
Virus Res; 2018 Aug; 255():165-170. PubMed ID: 30075160
[TBL] [Abstract][Full Text] [Related]
17. [Evolution of hepatitis B virus quasispecies during antiviral therapy in one chronic hepatitis B patient].
Liang PP; Guo JJ; Li QL; Luo Q; Shi XF; Huang AL
Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):516-20. PubMed ID: 22152243
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
19. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
[TBL] [Abstract][Full Text] [Related]
20. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Liu Y; Wang C; Zhong Y; Li X; Dai J; Ren X; Xu Z; Li L; Yao Z; Ji D; Wang L; Zhang L; Wong VW; Zoulim F; Xu D
J Viral Hepat; 2011 Apr; 18(4):e29-39. PubMed ID: 21392168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
